Determination of irinotecan and SN38 in human plasma by TurboFlow™ liquid chromatography–tandem mass spectrometry

• We developed TurboFlow™ LC–MS/MS method for quantify irinotecan and SN38.
• Turbulent Flow technology provides short time preparation.
• Full validation procedure certified to EMA and French COFRAC standard.
• This method is applicable and used for pharmacokinetic studies in clinical trial.

Irinotecan is a cytotoxic agent used in the treatment of metastatic colorectal cancer. Irinotecan is a prodrug when is converted in vivo to an active metabolite SN38, which has potent pharmacological activity. SN38 is then inactivated and excreted as SN38-glucuronide. High-performance liquid chromatography–mass spectrometry is a widely used bioanalysis technique that can be coupled to the turbulent-flow extraction line to shorten preparation time. A technique was developed to quantify irinotecan and its metabolite by liquid chromatography–tandem mass spectrometry coupled with a turbulent-flow online extraction method.Assays were performed on 100 μL of plasma after protein precipitation. The supernatant is injected directly into the extraction column, transferred to the chromatographic column, and analyzed by tandem mass spectrometry.Linearity, reproducibility and repeatability of the method were validated on a concentration range of 25–2500 ng/mL for irinotecan and 5–500 ng/mL for SN38. For the low limit of quantification of irinotecan and SN38, precision is 6.31% and 8.73%, and accuracy is 84.0% and 91.8%, respectively. The SN38-glucuronide determination protocol included a hydrolyzation step.This method was successfully used to quantify irinotecan, SN38 and SN38-G in human plasma in a clinical trial.